<scp>AT</scp>‐101 downregulates <scp>BCL</scp>2 and <scp>MCL</scp>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <scp>W</scp>aldenström macroglobulinaemia
Aneel Paulus(WinnMed), Asher Chanan‐Khan(WinnMed)
Cited by 36
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
|Blood|2011|450
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
|Blood|2017|271
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
|PubMed|2020|143
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
|Journal of the National Comprehensive Cancer Network|2019|94